CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.
about
Hib Vaccines: Past, Present, and Future PerspectivesAdjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigensA peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in miceDepletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunizationProtection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis modelImmunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levelsOuter membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM₁₉₇ conjugate vaccine.Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharidesTiming of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in miceImmunization with recombinant Sao protein confers protection against Streptococcus suis infection.Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune responseProtection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy.Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral ReseInduction of in vivo antipolysaccharide immunoglobulin responses to intact Streptococcus pneumoniae is more heavily dependent on Btk-mediated B-cell receptor signaling than antiprotein responses.AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses.Adjuvant effects of bacillus Calmette-Guerin DNA or CpG-oligonucleotide in the immune response to Taenia solium cysticercosis vaccine in porcine.Effects of LT-K63 and CpG2006 on phenotype and function of murine neonatal lymphoid cells.
P2860
Q26767144-EF6D05B2-657B-4B32-86F6-5C48DEBC1340Q28347424-51BBE3E3-4970-4289-A005-16638424330FQ31137207-DB33A74E-620B-45F2-95E3-72C721D3A90BQ33558995-DDF8FADD-97BA-4C23-84A6-BD0327944C80Q34005612-895E079F-7FC8-4633-AB44-CA0E6C646F01Q34008507-E2D7CAB5-84A3-4277-9571-F83F8894A8ECQ34492730-21A9CCB8-5EA9-4FC9-A1DC-83B1915D8374Q34492738-85C58F81-1CD0-460C-B045-2302AAEDC36EQ35066102-208FD4ED-E00D-49C3-987B-A1F8CF0B4FB7Q35139987-FA4952A6-74AD-4874-B8A8-2F20469FC701Q35943992-73EF7831-533C-4178-8BF0-02F98571AD08Q36097153-6110982D-6822-4860-989E-DD6253CA282DQ36911270-50F647B5-76AB-49FF-B265-9F86310393D3Q37074015-BE717398-8E47-4354-B4F5-4F16A300ACEFQ37282316-6E9EABEA-68FE-4D92-9BF9-17E886B6CE08Q38013202-AA848444-29B2-4B89-8045-1965AF3771CFQ38317118-623A8496-DE5A-40CA-97D5-6BF54BC8D5CBQ38947443-E3863FDD-D4EE-449B-94EA-0E3DC41C05E5Q43196580-B2428EDE-4BCB-47D2-A003-5C06D0ED180CQ44935178-8A7EC8B2-21BE-4B89-B558-D62ED3C5BFD3Q46894624-42744325-B89E-452A-B0F8-6A7DF1F1692DQ54434574-7FB57397-C24F-4F8B-9612-357BC46D8B45
P2860
CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
CpG oligodeoxynucleotides act ...... a (IgG2a) and IgG3 antibodies.
@ast
CpG oligodeoxynucleotides act ...... a (IgG2a) and IgG3 antibodies.
@en
CpG oligodeoxynucleotides act ...... ysaccharide immunoglobulin G2a
@nl
type
label
CpG oligodeoxynucleotides act ...... a (IgG2a) and IgG3 antibodies.
@ast
CpG oligodeoxynucleotides act ...... a (IgG2a) and IgG3 antibodies.
@en
CpG oligodeoxynucleotides act ...... ysaccharide immunoglobulin G2a
@nl
prefLabel
CpG oligodeoxynucleotides act ...... a (IgG2a) and IgG3 antibodies.
@ast
CpG oligodeoxynucleotides act ...... a (IgG2a) and IgG3 antibodies.
@en
CpG oligodeoxynucleotides act ...... ysaccharide immunoglobulin G2a
@nl
P2093
P2860
P1476
CpG oligodeoxynucleotides act ...... a (IgG2a) and IgG3 antibodies.
@en
P2093
C V Harding
J R Schreiber
N S Greenspan
P2860
P304
P356
10.1128/IAI.68.3.1450-1456.2000
P407
P577
2000-03-01T00:00:00Z